Adicet Bio, Inc. (ACET)
NASDAQ: ACET · Real-Time Price · USD
0.973
-0.027 (-2.66%)
At close: Feb 21, 2025, 4:00 PM
0.966
-0.008 (-0.79%)
After-hours: Feb 21, 2025, 4:50 PM EST
Adicet Bio Employees
Adicet Bio had 143 employees as of December 31, 2023. The number of employees increased by 11 or 8.33% compared to the previous year.
Employees
143
Change (1Y)
11
Growth (1Y)
8.33%
Revenue / Employee
n/a
Profits / Employee
-$824,364
Market Cap
80.21M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 143 | 11 | 8.33% |
| Dec 31, 2022 | 132 | 46 | 53.49% |
| Dec 31, 2021 | 86 | 4 | 4.88% |
| Dec 31, 2020 | 82 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
ACET News
- 17 days ago - Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement - Business Wire
- 22 days ago - Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 24 days ago - Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference - Business Wire
- 6 weeks ago - Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones - Business Wire
- 7 weeks ago - Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma - Business Wire
- 2 months ago - Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer - Business Wire
- 3 months ago - Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma - Business Wire